Inflection Strategy | Execution Risk Diagnostics for Late-Stage Biotech

The core conviction

They rarely fail because of the science.

30–40% of late-stage biotech failures are organizational, not scientific.

Biotech companies approaching their most critical moments rarely fail because of the molecule. They fail because the organization wasn't ready to carry the next stage. Where execution fails, talent was load-bearing.

The diagnostic is most valuable 6–18 months before the inflection event. The gap that looks manageable at 18 months becomes a crisis at 6.

What the diagnostic surfaces

The patterns that repeat.

These are the documented failure patterns of late-stage companies that had the science and still lost the inflection.

Misaligned leadership

The CEO, CMO, and CCO describe different priorities when interviewed separately. No one knows — until the moment of maximum external pressure.

No pre-built contingency

The board hasn't pre-authorized plans for the most likely adverse outcome. The first 72 hours after the readout are spent seeking alignment.

Fragmented FDA response

No single executive owns the FDA response. When an unexpected data query arrives, the response splits along functional lines.

Failure at the seams

Regulatory and commercial plans run on separate timelines and assumptions. The failure happens at the handoff, not inside either function.

Data built for the wrong job

Market access wasn't part of clinical data decisions. After approval, commercial inherits data designed for endpoints — not payers.

Unrehearsed disclosure

IR, legal, and the CEO haven't aligned on disclosure for the PDUFA decision. Conflicting signals reach investors within hours.

What the output looks like

An illustrative diagnostic signal.

A composite example of a late-stage biotech approaching commercialization, with positive clinical momentum.

Illustrative example · late-stage biotech · pre-launchElevated risk

Signals observed

Commercial readiness lagged milestone timing; launch-critical capabilities weren't aligned to the expected inflection.
A leadership transition blurred decision ownership, escalation, and execution speed.
Handoffs between regulatory, medical, market access, and commercial showed emerging strain as complexity grew.
Planning was milestone-aware, but not milestone-anchored.

Interpretation

No single finding signaled failure. The risk came from the interaction — leadership transition, readiness gaps, and cross-functional pressure compounding ahead of a critical event.

Recommended next step

Milestone-anchored readiness reviews, clarified executive decision governance, and commercial capabilities sequenced 12–18 months ahead of the inflection.

How it works

A structured diagnostic, not a template.

Fix the inflection

Pin down the moment you're approaching — readout, PDUFA, launch, or scale-up. Each carries a different risk profile.

Interview and score

Structured executive interviews, captured live in a purpose-built session instrument. Each area is rated Elevated, Watch, or Clear.

Report and act

A written report for the CEO and board: where risk sits, which handoffs are fragile, and what to fix first.

Before the inflection

Readiness Diagnostic

For companies 6–18 months from a readout, PDUFA date, or launch. A structured assessment of where execution risk sits, which handoffs are fragile, and what to fix first, while there is still time to fix it.

After a setback

Setback Review

For companies recovering from a Complete Response Letter, a missed endpoint, a delayed launch, or a restructuring. What broke organizationally, why, and which gaps still put the next milestone at risk.

Completed within three weeks of kickoff
6–12 confidential leadership interviews
Written review with ranked gaps, each paired with a specific fix
Readout with the CEO; optional session with the leadership team or board

What the framework covers

Leadership & organization

Executive alignment, decision governance, narrative discipline, human capital, organizational transition.

Commercial & access

Launch readiness and sequencing, market access, commercial operations, patient and physician adoption, post-approval scale-up.

Regulatory, clinical & operations

FDA strategy, medical affairs, biostatistics, manufacturing, pharmacovigilance, clinical data, AI and digital infrastructure.

Capital & strategy

Investor relations, capital markets, M&A and business development, portfolio allocation, loss of exclusivity, geopolitical risk.

Read the full framework explainer →

Executive Search

The right leader for the seat that matters.

When a diagnostic reveals a leadership gap, my search firm, Life Science Recruiters of North America, helps define the role and find the right leader. Companies that already know the seat they need can engage the search directly, on contingency.

I've spent a decade recruiting senior biopharma leaders across clinical, regulatory, medical and commercial functions, including recruiting across Ono Pharmaceutical's US scale-up from 8 to 138 people.

Diagnostic findings never depend on whether you engage the search. You're free to use any firm, or your own team.

Discuss a search →

About

Larry Chaityn, Principal

I have spent 25 years at the intersection of strategy, talent, and commercial execution in life sciences — in business development at Capgemini, consulting at Oracle Life Sciences, a decade of senior executive search, and as founder of an angel network's life sciences chapter.

"The same gap that looked manageable at 18 months out becomes a crisis at 6 months."

Across dozens of organizations at their most pressured moments, I saw the same execution failures repeat. They are not random. They are diagnosable. The Inflection Strategy Framework is the structure I built to find them.

This is not turnaround consulting. It is work for organizations that are fundamentally sound — before an inflection, or right after a setback — and need an outside view of their blind spots. When a diagnostic reveals a leadership gap, my search firm, Life Science Recruiters of North America, helps define the role and find the right leader.

Business Development Lead, Capgemini; Life Sciences Consulting, Oracle Life Sciences
Founder, Life Science Recruiters of North America; executive search at The Steely Group and Adecco Medical
Founder & Life Sciences Chapter Lead, Keiretsu Forum NY/Tri-State — presented 112 life sciences companies to angel investors
Author, At the Inflection on Substack

Connect

Approaching a critical inflection? Let's talk.

Start with a 30-minute readiness conversation, at no cost. Tell me where you are relative to your inflection, and I'll tell you where I'd look first. I respond to every inquiry personally.

Email: larry@inflectionstrategy.co
Location: New York, NY
LinkedIn: Larry Chaityn

Execution risk is diagnosable before it becomes a crisis.